Drug Profile
Irinotecan oral - Ascelia Pharma
Alternative Names: ASC-201 - Ascelia Pharma; OncoralLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Solural Pharma
- Developer Ascelia Pharma; Solural Pharma
- Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Gastric cancer
- No development reported Colorectal cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease) in Denmark (PO, Tablet)
- 25 Apr 2022 Phase-II clinical trials in Gastric cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Spain (PO) (EudraCT2021-003799-15)
- 17 Dec 2021 The US FDA approves IND application for irinotecan in gastric cancer